BIOLOG-ID
31.8.2021 11:53:07 CEST | Business Wire | Press release
After a public consultation, biolog-id, a global service provider of connected healthcare solutions, through its local partner ATC, has been awarded by the Ministry of Health to deploy Biolog Transfusion Solution in Kuwait Central Blood Bank (KCBB), the national blood bank operator.
Over the years, KCBB has reached a very high scientific level and has acquired a well-deserved reputation for the quality of its blood supply chain. In the Middle East region, this institution is recognized as a leading institution for the quality of its blood supply processes and as an early adopter of leading-edge innovation. On the international stage, the KCBB has also been a pioneer in the AABB (American Association of Blood Banks) accreditation and is for long a member and significant contributor to the ISBT’s (International Society of Blood Transfusion) recommendations.
While the COVID-19 pandemic has challenged the transfusion supply chain, KCBB has chosen to adopt the cutting-edge technology Biolog Transfusion Solution to better drive its operations. Based on RFID, this modular solution combines tags, equipment, and software to offer accurate visibility on blood products throughout the transfusion chain. Designed for healthcare professionals, the solution will support KCBB to enhance GMPs and safety for all processed blood units (Red Blood Cells, Platelets & Plasma).
“We are very honored that KCBB relies on our technology to optimize its processes and its blood distribution tracking”, states Philippe Jacquet, Executive Director of Sales EMEA/LATAM at biolog-id. “This major achievement has been facilitated by our partner in Kuwait, Advanced Technology Company (ATC), who has been instrumental in the management of this project and who will coordinate the implementation of our solution”.
“ATC is very pleased and honored to have been awarded for this project, which will be the first implementation of the state-of-the-art Biolog Transfusion Solution at the prestigious Kuwait Central Blood Bank and its branches. This implementation will definitively be a millstone in the midst of continuous improvement of blood supply safety and blood processing in Kuwait” said M. Mahmoud Chehime, Director – Specialty Diagnostics & LS at ATC.
Biolog Transfusion Solution will be deployed in the Kuwait Central Blood Bank as well as three distant Blood Banks. This implementation will strengthen biolog-id’s presence in the Middle East region, already installed in Egypt and Saudi Arabia.
About biolog-id
:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and Xerys Invest. Xerys Invest is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About Kuwait Central Blood Bank:
The Kuwait Central Blood Bank’s (KCBB) mission is meeting the country’s needs of the patients for safe, high quality and provision of all transfusion services under the supervision of the government. Provision of educational materials and introduction of awareness of the importance of the blood donation to the public.
KCBB URL: www.kuwaitcentralbloodbank.wordpress.com
About Advanced Technology Company:
ATC is a medical equipment supplier to the Kuwait healthcare sector since 1981. Over time, the Company has become the leading distributor and marketer of state-of-the-art healthcare and environmental products and services.
ATC URL: www.atc.com.kw
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005479/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom